Lacosamide Fresenius Kabi

Lacosamide, the active ingredient in Lacosamide Fresenius Kabi, is an anticonvulsant presented as an intravenous solution for intravenous use. It is indicated for the treatment of partial‑onset seizures in patients with epilepsy, helping to control seizure activity and improve neurological stability.

GNH USA supplies Lacosamide Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this essential antiepileptic medication. The product complies with European Union regulatory standards and is manufactured under strict quality controls.

Lacosamide is an anticonvulsant used in the management of seizure disorders.

Partial‑onset seizures (focal seizures): reduces seizure frequency as adjunctive therapy in epilepsy patients. Epilepsy (focal epilepsy): provides additional seizure control when added to existing antiepileptic regimens. Refractory epilepsy: offers an alternative mechanism of action for patients whose seizures are not adequately controlled by other medications.

Lacosamide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness - Headache - Nausea - Fatigue - Diplopia (double vision) - Somnolence

Serious or Rare Side Effects: - Cardiac conduction abnormalities (e.g., PR interval prolongation, atrial fibrillation) - Severe skin reactions such as Stevens‑Johnson syndrome - Suicidal ideation or behavior - Respiratory depression - Significant hepatic enzyme elevations - Allergic reactions including anaphylaxis

When using Lacosamide, clinicians should consider several safety aspects.

Renal impairment: adjust monitoring as the drug is primarily excreted unchanged by the kidneys. Hepatic impairment: use caution and monitor liver function tests regularly. Cardiac conduction disorders: obtain baseline ECG and monitor for PR‑interval changes. Pregnancy: prescribe only if the potential benefit justifies the potential risk to the fetus. Concomitant CNS depressants: may increase sedation and respiratory depression. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Lacosamide can interact with other medicines, affecting its safety or efficacy.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine): may exacerbate PR‑interval prolongation. - Carbamazepine: can reduce lacosamide plasma concentrations. - Other sodium‑channel blockers (e.g., phenytoin, lamotrigine): additive effects on cardiac conduction.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluconazole): may increase lacosamide exposure. - CNS depressants (e.g., benzodiazepines): may enhance sedation. - Diuretics: may affect renal clearance of lacosamide.